The effect of antidepressants on lipid homeostasis: a cardiac safety concern?
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The authors sought to summarise and synthesise results from investigations which report on the effect of antidepressants on serum lipid homeostasis. METHOD: The authors conducted a MedLine search of all English-language articles from 1966 to March 2006 using the search terms: major depressive disorder, bipolar disorder, lipids, triglycerides, cholesterol, low-density lipoprotein, high-density lipoprotein, and the non-proprietary names of conventional antidepressants indicated for the treatment of major depressive disorder in North America as of March 2006. The search was supplemented with a manual review of retrieved articles for any further citations reporting the effects of antidepressants on lipid homeostasis. RESULTS: Despite the paucity of well-characterised investigations, the unfavourable effect of weight gain promoting antidepressants (e.g., tricyclics, mirtazapine) on serum lipid parameters (i.e., triglycerides and low-density lipoprotein cholesterol) is a consistent finding. Weight-neutral antidepressants (e.g., bupropion, venlafaxine, duloxetine), however, are less likely to disrupt the lipid milieu. A weight-independent effect on lipid homeostasis is less consistently reported. CONCLUSION: Some antidepressants unfavourably influence the lipid milieu; mediating factors other than weight gain are not well-established. Pivotal studies evaluating the therapeutic index of antidepressants need to systematically collect and report data on the lipid effects of antidepressants.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Excess Mortality in Bipolar and Unipolar Disorder in Sweden
Ösby, U., Brandt, L., Correia, N., Ekbom, A., & Sparén, P. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.9.844 · Cited by 1,120 · cited 1×
“Mortality studies indicate that CAD is the most frequent cause of premature mortality in individuals with mood and psychotic disorders [3,4].”
BackgroundHypertriglyceridemia as a cardiovascular risk factor
Austin, M. A., Hokanson, J. E., & Edwards, K. L. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)00031-9 · Cited by 1,066 · cited 12×
“A direct association between LDL-C (and total cholesterol), and new-onset CAD, or recurrent coronary events, has been reported in population-based studies [6].”
BackgroundInfluentialMortality and causes of death in schizophrenia in Stockholm County, Sweden
Ösby, U., Correia, N., Brandt, L., Ekbom, A., & Sparén, P. (2000) · Schizophrenia Research · doi:10.1016/s0920-9964(99)00191-7 · Cited by 679 · cited 1×
“Mortality studies indicate that CAD is the most frequent cause of premature mortality in individuals with mood and psychotic disorders [3,4].”
BackgroundDuloxetine in the Treatment of Major Depressive Disorder: A Double-Blind Clinical Trial
Goldstein, D. J., Mallinckrodt, C., Lu, Y., & Demitrack, M. A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0309 · Cited by 334 · cited 1×
“Venlafaxine and duloxetine inhibit serotonin and noradrenaline transporters, with pharmacological properties similar to the US FDA-approved bariatric treatment, sibutramine [34-39].”
BackgroundBupropion SR Enhances Weight Loss: A 48‐Week Double‐Blind, Placebo‐ Controlled Trial
Anderson, J. W., Greenway, F. L., Fujioka, K., Gadde, K. M., McKenney, J., & O'Neil, P. M. (2002) · Obesity Research · doi:10.1038/oby.2002.86 · Cited by 315 · cited 2×
“These results cohere with a 24-week placebo-controlled study with sustained-release (SR) bupropion (300 – 400 mg/day) in which bupropion SR-treated subjects exhibited a significant increase in HDL-C and a decrease in fasting serum triglycerides [40].”
BackgroundResultEvidence of the dual mechanisms of action of venlafaxine
Harvey, A. T., Rudolph, R. L., & Preskorn, S. H. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.5.503 · Cited by 302 · cited 1×
“Venlafaxine and duloxetine inhibit serotonin and noradrenaline transporters, with pharmacological properties similar to the US FDA-approved bariatric treatment, sibutramine [34-39].”
BackgroundBupropion SR vs. Placebo for Weight Loss in Obese Patients with Depressive Symptoms
Jain, A. K., Kaplan, R. A., Gadde, K. M., Wadden, T. A., Allison, D. B., Brewer, E. R., Leadbetter, R. A., Richard, N., Haight, B., Jamerson, B. D., et al. (2002) · Obesity Research · doi:10.1038/oby.2002.142 · Cited by 205
Deisenhammer, E. A., Kramer-Reinstadler, K., Liensberger, D., Kemmler, G., Hinterhuber, H., & Wolfgang Fleischhacker, W. (2004) · Psychiatry Research · doi:10.1016/j.psychres.2003.09.007 · Cited by 92 · cited 1×
“This is somewhat surprising in light of: 1) the bidirectional association between CAD and major depressive disorder; and 2) the epidemiological association between altered (low or lowered) serum cholesterol levels and morbidity from depression, suicide, homicide and violence [17-20].”
BackgroundKopf, D., Westphal, S., Luley, C. W., Ritter, S., Gilles, M., Weber-Hamann, B., Lederbogen, F., Lehnert, H., Henn, F. A., Heuser, I., et al. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000138762.23482.63 · Cited by 92
Sonawalla, S. B., Papakostas, G. I., Petersen, T. J., Yeung, A. S., Smith, M. M., Sickinger, A. H., Gordon, J., Israel, J. A., Tedlow, J. R., Lamon-Fava, S., et al. (2002) · Psychosomatics · doi:10.1176/appi.psy.43.4.310 · Cited by 62
Cited by
Correll, C. U., Detraux, J., De Lepeleire, J., & De Hert, M. (2015) · World Psychiatry · doi:10.1002/wps.20204 · Cited by 820
“Although some antidepressants have been associated with weight gain (23,41), which is a risk factor for lipid abnormalities, data on adverse lipid effects of these medications remain scarce, and most antidepressants have not been associated with dyslipidemia (48) (Table 2).”
BackgroundCarvalho, A. F., Sharma, M. S., Brunoni, A. R., Vieta, E., & Fava, G. A. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000447034 · Cited by 650
Kennedy, S. H., Lam, R. W., Parikh, S. V., Patten, S. B., & Ravindran, A. V. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.06.043 · Cited by 525
Self-citationLam, R. W., Kennedy, S. H., Grigoriadis, S., McIntyre, R. S., Milev, R., Ramasubbu, R., Parikh, S. V., Patten, S. B., & Ravindran, A. V. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.06.041 · Cited by 431
“Metabolic adverse events include appetite stimulation, weight gain, disturbances in the lipid milieu and glucose homeostasis (McIntyre et al., 2006).”
BackgroundSelf-citationVan Reedt Dortland, A. K. B., Giltay, E. J., Van Veen, T., Zitman, F. G., & Penninx, B. W. J. H. (2010) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2010.01565.x · Cited by 191
Metadata
- Authors
- McIntyre, R. S., Soczynska, J. K., Konarski, J. Z., & Kennedy, S. H.
- Venue
- Expert Opinion on Drug Safety
- Publisher
- Informa Healthcare
- Published
- 2006-06-15
- Volume
- 5
- Issue
- 4
- Pages
- 523-537
- ISSN
- 1474-0338 (ISSN-L)
- 1744-764X
- OpenAlex
- W2032077631
- Cited by
- 77
- References
- 10
- FWCI
- 3.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The effect of antidepressants on lipid homeostasis: a cardiac safety concern? https://app.cochat.ai/papers/10.1517/14740338.5.4.523
- The paper
- McIntyre, R. S., Soczynska, J. K., Konarski, J. Z., & Kennedy, S. H. (2006). The effect of antidepressants on lipid homeostasis: a cardiac safety concern? Expert Opinion on Drug Safety. https://doi.org/10.1517/14740338.5.4.523
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.